Notice: This company has been marked as potentially delisted and may not be actively trading. Provention Bio (PRVB) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Macrogenics Inc MGNXDecember 29, 2023 | morningstar.comCambridge Investment Research Advisors Inc. Increases Stock Holdings in Provention Bio, Inc. (NASDAQ:PRVB)Cambridge Investment Research Advisors Inc. boosted its position in shares of Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) by 86.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,895 shares of the company's stock afMay 29, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Stock Holdings Increased by Swiss National BankSwiss National Bank raised its holdings in shares of Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) by 47.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 187,100 shares of the company's stock afMay 26, 2023 | marketbeat.comArizona State Retirement System Purchases 7,068 Shares of Provention Bio, Inc. (NASDAQ:PRVB)Arizona State Retirement System increased its position in Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) by 47.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,860 shares of the company's stock after buying an adMay 25, 2023 | marketbeat.comSG Americas Securities LLC Purchases New Position in Provention Bio, Inc. (NASDAQ:PRVB)SG Americas Securities LLC acquired a new position in shares of Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 10,354 shares of the company's stock, valued at approximately $109,000. Several other large investoMay 17, 2023 | marketbeat.comZurcher Kantonalbank Zurich Cantonalbank Boosts Stock Holdings in Provention Bio, Inc. (NASDAQ:PRVB)Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) by 169.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,427 shareMay 8, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Given Consensus Rating of "Hold" by BrokeragesProvention Bio, Inc. (NASDAQ:PRVB - Get Rating) has earned an average recommendation of "Hold" from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy ratinMay 7, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Shares Purchased by New York State Common Retirement FundNew York State Common Retirement Fund increased its position in shares of Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) by 28.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,909 shares of the company'May 3, 2023 | marketbeat.comSanofi/Provention: innovative diabetes drug is a good fitMay 1, 2023 | finance.yahoo.comThose who invested in Provention Bio (NASDAQ:PRVB) a year ago are up 456%April 29, 2023 | finance.yahoo.comSanofi completes Provention Bio acquisitionApril 28, 2023 | seekingalpha.comEarnings Preview: Provention Bio, Inc. (PRVB) Q1 Earnings Expected to DeclineApril 27, 2023 | finance.yahoo.comTrading was temporarily halted for "PRVB" at 07:04 PM with a stated reason of "News pending."April 27, 2023 | marketbeat.comSanofi - Aventis Groupe: Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 27, 2023 | finanznachrichten.deProvention Bio gains after HSR waiting period for Sanofi deal expiredApril 26, 2023 | seekingalpha.comPress Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.April 26, 2023 | benzinga.comPRVB Apr 2023 23.000 putApril 22, 2023 | finance.yahoo.comProvention Bio, Inc. (NASDAQ:PRVB) Receives Average Recommendation of "Hold" from AnalystsShares of Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) have received a consensus recommendation of "Hold" from the seven analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the coApril 12, 2023 | marketbeat.comSanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More InformationApril 11, 2023 | msn.comRice Hall James & Associates LLC Has $1.92 Million Holdings in Provention Bio, Inc. (NASDAQ:PRVB)Rice Hall James & Associates LLC trimmed its position in Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) by 17.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,980 shares of the company's stock aApril 9, 2023 | marketbeat.comOppenheimer Equities Analysts Cut Earnings Estimates for Provention Bio, Inc. (NASDAQ:PRVB)Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) - Research analysts at Oppenheimer reduced their FY2023 earnings per share estimates for Provention Bio in a report issued on Wednesday, March 29th. Oppenheimer analyst J. Kim now expects that the company will earn ($1.71) per share for the year, doApril 3, 2023 | marketbeat.comProvention Bio, Inc. (NASDAQ:PRVB) Just Reported And Analysts Have Been Cutting Their EstimatesApril 2, 2023 | finance.yahoo.comGaithersburg’s Novavax locks in consulting deal with outgoing R&D headMarch 27, 2023 | bizjournals.comProvention Bio, Inc. (NASDAQ:PRVB) Given Average Recommendation of "Hold" by AnalystsProvention Bio, Inc. (NASDAQ:PRVB - Get Rating) has been assigned a consensus recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. The avMarch 18, 2023 | marketbeat.com(PRVB): Johnson Fistel Investigates Proposed Sale of Provention Bio Inc.; Is $25.00 a Fair Price?March 17, 2023 | benzinga.comQ4 2022 MacroGenics Inc Earnings CallMarch 16, 2023 | finance.yahoo.comProvention Bio's Earnings OutlookMarch 15, 2023 | benzinga.comProvention Bio (NASDAQ:PRVB) Earns "Neutral" Rating from Sumitomo Mitsui Financial GroupSumitomo Mitsui Financial Group restated a "neutral" rating and issued a $25.00 price target (up previously from $15.00) on shares of Provention Bio in a research note on Tuesday.March 15, 2023 | marketbeat.comSMBC Nikko Downgrades Provention Bio (PRVB)March 14, 2023 | msn.comJefferies Downgrades Provention Bio (PRVB)March 14, 2023 | msn.comProvention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealMarch 14, 2023 | proactiveinvestors.comShort Volatility Alert: Provention Bio IncMarch 14, 2023 | benzinga.com4 Analysts Have This to Say About Provention BioMarch 14, 2023 | markets.businessinsider.comShareholder Alert: Ademi LLP investigates whether Provention Bio, Inc. has obtained a Fair Price in its transaction with SanofiMarch 13, 2023 | benzinga.comProvention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference CallMarch 13, 2023 | finance.yahoo.comSanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drugMarch 13, 2023 | msn.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Provention Bio, Inc. BuyoutMarch 13, 2023 | benzinga.comPRVB STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Provention Bio, Inc. Is Fair to ShareholdersMarch 13, 2023 | businesswire.comWhy Is Provention Bio (PRVB) Stock Up 263% Today?March 13, 2023 | investorplace.comProvention Bio Stock Soars on $2.9 Billion Acquisition by SanofiMarch 13, 2023 | barrons.comSanofi to Acquire Provention Bio for Around $2.9 BlnMarch 13, 2023 | wsj.comFrance's Sanofi to acquire US-based Provention Bio for $2.9 blnMarch 13, 2023 | reuters.comSanofi To Buy Provention Bio For Around $2.9 Bln In CashMarch 13, 2023 | markets.businessinsider.comUPDATE 1-France's Sanofi to acquire US-based Provention Bio for $2.9 blnMarch 13, 2023 | finance.yahoo.comSanofi to buy Provention Bio in deal worth $2.9 billionMarch 13, 2023 | finance.yahoo.comWill Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should KnowMarch 9, 2023 | finance.yahoo.comProvention Bio (PRVB) Scheduled to Post Quarterly Earnings on ThursdayProvention Bio (NASDAQ:PRVB) will be releasing earnings before the market opens on Thursday, March 16, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=504040)March 9, 2023 | marketbeat.com390,800 Shares in Provention Bio, Inc. (NASDAQ:PRVB) Purchased by Palo Alto Investors LPPalo Alto Investors LP purchased a new position in Provention Bio, Inc. (NASDAQ:PRVB - Get Rating) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 390,800 shares of the company's stock, vMarch 6, 2023 | marketbeat.comProvention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A WorryFebruary 24, 2023 | seekingalpha.comProvention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023February 23, 2023 | finance.yahoo.com Get Provention Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025. Click here to see the surprising reason why PRVB Media Mentions By Week PRVB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRVB News Sentiment▼1.560.44▲Average Medical News Sentiment PRVB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRVB Articles This Week▼00▲PRVB Articles Average Week Get Provention Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PRVB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Roivant Sciences News Today Viking Therapeutics News Today Legend Biotech News Today Ascendis Pharma A/S News Today Madrigal Pharmaceuticals News Today Jazz Pharmaceuticals News Today Elanco Animal Health News Today Cytokinetics News Today Nuvalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRVB) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provention Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provention Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
